Skip to main content

Novel Therapeutic Approaches

  • Chapter
Pediatric Oncology

Part of the book series: M.D. Anderson Cancer Care Series ((MDCCS,volume 4))

  • 1018 Accesses

Abstract

During the latter part of the twentieth century, substantial improvements were made in the treatment of childhood cancers. Fifty years ago, most pediatric cancers were fatal. Today, however, more than 75% of pediatric patients with cancer survive the disease. Most advances have been achieved through extensive research and well-designed clinical trials. Investigators continue to explore novel therapies with the goals of providing salvage treatment to patients whose disease does not respond to current therapies and of improving the efficacy and safety of frontline regimens. Recent advances in the fields of genetics, immunology, and molecular biology have led to a better understanding of childhood cancers, which in turn has led to the rational design of drugs based on a thorough understanding of targets on or inside malignant cells. Such an approach aims to further improve cure rates and reduce toxicity. This chapter describes the novel therapies available to pediatric patients at M. D. Anderson Cancer Center. We describe the difficulties of conducting innovative research in children as well as how multidisciplinary interactions at M. D. Anderson help children quickly and safely benefit from novel therapies, including stem cell transplantation for leukemia, lymphoma, and other solid tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

eBook
USD 16.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Suggested Readings

  • Aleksa K, Koren G. Ethical issues in including pediatric cancer patients in drug development trials. Paediatr Drugs 2002;4:257–265.

    PubMed  Google Scholar 

  • Apisarnthanarax N, Donato M, Korbling M, et al. Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results. Bone Marrow Transplant 2003;31:459–465.

    Article  CAS  PubMed  Google Scholar 

  • Couriel DR, Hicks K, Giralt S, et al. Phase III trial with infliximab/ methylprednisolone (MP) vs (MP) for the treatment of acute GVHD: preliminary findings. Biol Blood Marrow Transplant 2003a;9:95.

    Article  Google Scholar 

  • Couriel DR, Hicks K, Saliba R, et al. Sirolimus (Rapamycin) for treatment of steroid-refractory chronic graft versus host disease. Biol Blood Marrow Transplant 2003b;9:67.

    Article  Google Scholar 

  • Goldberg JD, Jacobsohn DA, Margolis J, et al. Pentostatin for the treatment of chronic graft-versus-host disease in children. J Pediatr Hematol Oncol 2003;25:584–588.

    Article  PubMed  Google Scholar 

  • Jeha S, Gandhi V, Chan KW, et al. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood 2004;103:784–789.

    Article  CAS  PubMed  Google Scholar 

  • Kleinerman ES. Biological therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide. Hematol Oncol Clin North Am 1995;9:927–938.

    CAS  PubMed  Google Scholar 

  • Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrowtransplantation, and 13-cis-retinoic acid. N Engl J Med 1999;341:1165–1173.

    Article  CAS  PubMed  Google Scholar 

  • Nahata MC. Need for conducting research on medications unlabeled for use in pediatric patients. Ann Pharmacother 1994;9:1103–1104.

    Google Scholar 

  • Przepiorka D, Blamble D, Hilsenbeck S, et al. Tacrolimus clearance is agedependent within the pediatric population. Bone Marrow Transplant 2002;26:601–605.

    Article  Google Scholar 

  • Reaman GH. Pediatric oncology: current views and outcomes. Pediatr Clin North Am 2002;6:1305–1318.

    Article  Google Scholar 

  • Roberts R, Rodriguez W, Murphy D, Crescenzi T. Pediatric drug labeling. JAMA 2003;290:905–911.

    Article  PubMed  Google Scholar 

  • Sleight B, Chan K, Serrano A, et al. Infliximab for GVHD therapy in children. Biol Blood Marrow Transplant 2003;9:96.

    Article  Google Scholar 

  • Somberg JC. Pediatric drug development. Am J Ther 2003;10:2.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer Science+Business Media, Inc.

About this chapter

Cite this chapter

Jeha, S.S., Worth, L.L. (2005). Novel Therapeutic Approaches. In: Chan, K.W., Raney, R.B. (eds) Pediatric Oncology. M.D. Anderson Cancer Care Series, vol 4. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-24472-3_14

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-24472-3_14

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-387-24470-9

  • Online ISBN: 978-0-387-24472-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics